MarketCap
Facebook
X
Telegram
Galecto Market Cap | GLTO
As of November 12, 2026 Galecto has a market cap of $ 762 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Galecto
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 935 K | 51.6 M | 76.5 M | 89 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 89 M | 935 K | 54.5 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
311 M | - | - | $ 24.9 M |  USA |
 |
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
541 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
73.5 M | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
179 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
101 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
2.98 B | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
47.3 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
769 M | $ 4.2 | -0.36 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
400 B | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
3.19 M | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
Achieve Life Sciences
ACHV
|
126 M | $ 6.78 | 0.89 % | $ 296 M | USA |
 |
Axon Enterprise
AXON
|
30.6 B | $ 316.97 | 4.77 % | $ 24.7 B | USA |
|
TFF Pharmaceuticals
TFFP
|
10.8 M | - | -60.05 % | $ 125 K | USA |
 |
Bristol-Myers Squibb Company
BMY
|
122 B | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M |  Britain |
 |
Axcella Health
AXLA
|
25 M | - | -16.42 % | $ 249 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
7.55 M | $ 58.59 | 4.29 % | $ 7.04 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
1.73 B | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
40.8 B | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
198 B | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
1.45 M | - | -33.86 % | $ 61.2 M | USA |
 |
Codiak BioSciences
CDAK
|
243 M | - | -55.98 % | $ 2.15 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
10.5 B | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
379 B | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
1.63 M | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
BioLineRx Ltd.
BLRX
|
5.65 B | $ 1.49 | -1.97 % | $ 3.67 B | Israel |
 |
Sage Therapeutics
SAGE
|
434 M | - | - | $ 527 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
421 M | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
81 M | - | - | $ 121 M | USA |
 |
TCR2 Therapeutics
TCRR
|
57.9 M | - | - | $ 58.1 M | USA |
 |
C4 Therapeutics
CCCC
|
234 M | $ 2.9 | -3.5 % | $ 240 M | USA |
 |
Eli Lilly and Company
LLY
|
940 B | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
427 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Compugen Ltd.
CGEN
|
196 M | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
4.11 B | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
GeoVax Labs
GOVX
|
1.23 M | $ 2.13 | -20.4 % | $ 2.04 M | USA |
 |
Unity Biotechnology
UBX
|
28.1 M | - | -33.41 % | $ 3.37 M | USA |
 |
MediciNova
MNOV
|
69.2 M | $ 1.41 | 0.36 % | $ 69.2 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
122 M | - | - | $ 521 M | USA |
 |
Seelos Therapeutics
SEEL
|
5.44 M | - | -47.76 % | $ 6.27 M | USA |
 |
Celldex Therapeutics
CLDX
|
2.04 B | $ 30.18 | -1.53 % | $ 2 B | USA |
 |
Moderna
MRNA
|
19.4 B | $ 248.62 | -0.88 % | $ 96.7 B | USA |